Medicine & Life Sciences
Neoplasms
100%
Breast Neoplasms
39%
Survival
38%
Mutation
31%
Neoplasm Metastasis
27%
Carcinoma
27%
Adenocarcinoma
26%
Therapeutics
24%
Genes
23%
Drug Therapy
21%
Melanoma
20%
Acute Myeloid Leukemia
20%
Recurrence
18%
Glioma
17%
Biomarkers
17%
Non-Small Cell Lung Carcinoma
17%
Lung Neoplasms
16%
Lymphoma
15%
Pancreatic Neoplasms
15%
Glioblastoma
14%
Proteins
14%
Prostatic Neoplasms
14%
Breast
13%
Apoptosis
13%
Growth
13%
Carcinogenesis
12%
Cell Line
12%
Lymphoma, Large B-Cell, Diffuse
12%
Biopsy
12%
Immunohistochemistry
12%
B-Cell Chronic Lymphocytic Leukemia
12%
DNA
12%
Colorectal Neoplasms
12%
Squamous Cell Carcinoma
11%
Lymph Nodes
11%
Lung
11%
Bone Marrow
11%
Skin
10%
Ovarian Neoplasms
10%
Adenocarcinoma of Lung
10%
Fine Needle Biopsy
10%
Pathologists
10%
Sarcoma
10%
MicroRNAs
10%
Renal Cell Carcinoma
10%
T-Lymphocytes
10%
Leukemia
10%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9%
Mantle-Cell Lymphoma
9%
Radiotherapy
9%
Pathology
9%
Gene Expression
9%
Myelodysplastic Syndromes
9%
Phenotype
9%
Endometrial Neoplasms
9%
Anaplastic Large-Cell Lymphoma
9%
Progression-Free Survival
9%
Fluorescence In Situ Hybridization
9%
ErbB Receptors
8%
B-Cell Lymphoma
8%
Estrogen Receptors
8%
Triple Negative Breast Neoplasms
8%
Staining and Labeling
8%
Cell Biology
8%
Inflammatory Breast Neoplasms
8%
Epithelial-Mesenchymal Transition
8%
Neoadjuvant Therapy
7%
B-Lymphocytes
7%
Genome
7%
Cytogenetics
7%
High-Throughput Nucleotide Sequencing
7%
Stem Cells
7%
Methylation
7%
Non-Hodgkin's Lymphoma
7%
Squamous Cell Carcinoma of Head and Neck
6%
Neoplastic Stem Cells
6%
Protein-Tyrosine Kinases
6%
Immunotherapy
6%
Urinary Bladder Neoplasms
6%
Loss of Heterozygosity
6%
Residual Neoplasm
6%
Tumor Microenvironment
6%
In Vitro Techniques
6%
Neck
6%
T-Cell Lymphoma
6%
Prostate
6%
Phosphotransferases
6%
Clinical Trials
6%
Chromosome Aberrations
6%
Polymerase Chain Reaction
6%
Confidence Intervals
6%
Heterografts
6%
Epithelial Cells
6%
Down-Regulation
6%
Chromosomes
6%
Neuroendocrine Carcinoma
6%
Oncogenes
6%
Hodgkin Disease
6%
Messenger RNA
6%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5%